COLIGROW: Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction

Sponsor
Hospital Universitario 12 de Octubre (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05774236
Collaborator
Spanish Clinical Research Network - SCReN (Other), Instituto de Salud Carlos III (Other)
172
3
2
30.1
57.3
1.9

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare how two methods for cervical ripening work in a population of singleton pregnancies with late-onset fetal growth restriction (FGR) at term.

The main question it aims to answer is whether Cook´s balloon (a mechanical method) is superior to vaginal dinoprostone (a pharmacological method) in achieving a vaginal delivery, without increasing neonatal morbidity.

Participants will be randomized to receive Cook´s balloon (experimental group) or vaginal dinoprostone (control group) for cervical ripening.

Researchers will compare both groups to see if Cook´s balloon is associated with a higher rate of vaginal delivery than vaginal dinoprostone and is not related to increased neonatal morbidity.

Condition or Disease Intervention/Treatment Phase
  • Device: Cook´s balloon
  • Drug: Vaginal dinoprostone
Phase 3

Detailed Description

Late-onset fetal growth restriction (FGR) represents the most common subtype of FGR (70-80%). The greatest risk for these fetuses appears once term pregnancy is reached, when stressful situations are added to their status of relative hypoxia, such as the appearance of contractions and funicular compression. Thus, it has been shown that from week 37-38 the risk of intrauterine mortality increases and there is a general consensus not to prolong these pregnancies beyond this period. In this situation, induction of labor is usually preferred over elective caesarean delivery. However, these fetuses have an increased risk of cesarean section for suspected fetal distress.

Mechanical methods for cervical ripening are associated with less uterine stimulation with a lower rate of tachysystole than prostaglandins. Therefore, these methods have been proposed as the optimal approach for late-onset FGR, since they could reduce the rate of cesarean sections for suspected fetal distress. However, there is no published randomized controlled trials on the use of different methods of cervical ripening for labor induction in late-onset FGR.

Thus, the investigators postulate that, in late-onset FGR, cervical ripening with a mechanical method (Cook´s balloon) achieves a higher percentage of vaginal deliveries than a pharmacological method (vaginal dinoprostone), being safe for both the mother and the newborn.

The main aim of this study is to evaluate whether cervical ripening with Cook balloon for labor induction at term gestation of singleton pregnancies with late-onset FGR achieves a higher rate of vaginal delivery compared to the use of vaginal dinoprostone, without increasing neonatal morbidity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
172 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
multicenter, randomized (1:1), open-label, 2-arm parallel group, controlled trialmulticenter, randomized (1:1), open-label, 2-arm parallel group, controlled trial
Masking:
None (Open Label)
Masking Description:
No masking
Primary Purpose:
Treatment
Official Title:
Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction (COLIGROW)
Anticipated Study Start Date :
Mar 27, 2023
Anticipated Primary Completion Date :
May 27, 2025
Anticipated Study Completion Date :
Sep 27, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cook´s balloon

Silicone 80 mL double-balloon cervical ripening catheter with an adjustable-length malleable stylet

Device: Cook´s balloon
Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
Other Names:
  • Cook® Cervical Ripening Balloon with Stylet
  • Double balloon catheter
  • Active Comparator: Vaginal dinoprostone

    Vaginal delivery system containing 10 mg dinoprostone (Prostaglandin E2) dispersed throughout its matrix and releasing approximately 0.3 mg/hour dinoprostone over a 24-hour period.

    Drug: Vaginal dinoprostone
    Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
    Other Names:
  • Dinoprostone vaginal insert
  • Controlled-release dinoprostone delivery system
  • Vaginal prostaglandin E2
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of vaginal delivery [2 days (from admission to delivery)]

      To assess whether cervical ripening with a Cook balloon for induction of labor of term pregnancies with FGR increases the rates of vaginal delivery with respect to the use of vaginal dinoprostone, without increasing neonatal morbidity.

    Secondary Outcome Measures

    1. Rate of cesarean sections due to suspected fetal distress [2 days (from admission to delivery)]

      To assess whether cervical ripening with a Cook balloon for induction of labor of term pregnancies with FGR decreases the rates of cesarean sections due to suspected fetal distress with respect to the use of vaginal dinoprostone

    2. Induction-to-delivery interval [2 days (from admission to delivery)]

      Comparison of the time interval between the onset of cervical ripening and delivery between the two arms

    3. Neonatal morbidity [From delivery to discharge of the newborn (up to 1 month)]

      To analyze the neonatal morbidity through the MAIN score (Morbidity assessment index for newborns) of neonatal morbidity and the duration of admissions to the Neonatal Intensive Care Unit (NICU).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Singleton pregnancy

    • Age ≥ 18 years

    • Gestational age (GA) dated by first trimester ultrasound ≥ 37+0 weeks

    • Cephalic presentation

    • Stage I fetal growth restriction, defined as the presence of at least one of these two criteria:

    1. Estimated fetal weight (EFW) < 3rd percentile

    2. EFW < 10th percentile and at least one of the following: 2.1) Umbilical artery pulsatility index > 95th percentile or 2.2) Cerebral-placental index < 5th percentile

    • Bishop score < 7

    • Intact fetal membranes

    • No previous caesarean section

    • No contraindications for vaginal delivery or labor induction.

    Exclusion Criteria:
    • Major fetal malformation

    • Fetal genetic abnormality

    • Fetal congenital infection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Sant Joan de Déu Esplugues de Llobregat Barcelona Spain 08950
    2 Hospital Clinic i Provincial Barcelona Spain 08028
    3 Hospital Universitario 12 de Octubre Madrid Spain 28041

    Sponsors and Collaborators

    • Hospital Universitario 12 de Octubre
    • Spanish Clinical Research Network - SCReN
    • Instituto de Salud Carlos III

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ignacio Herraiz, Adjunct professor, Hospital Universitario 12 de Octubre
    ClinicalTrials.gov Identifier:
    NCT05774236
    Other Study ID Numbers:
    • COLIGROW
    • 2021-001726-22
    • PI19_01005
    First Posted:
    Mar 17, 2023
    Last Update Posted:
    Mar 23, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ignacio Herraiz, Adjunct professor, Hospital Universitario 12 de Octubre
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 23, 2023